Article
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
All News
Dr. John Cush
Tweet
Future therapies for IgG4 re dz. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/3pwBiBTf2N
Dr. Rachel Tate
Tweet
“Pathology is helpful but not diagnostic” Dr. Dua #RWCS23 @RheumNow here are your features found on biopsy. https://t.co/J9a6S9XY2D
Dr. Rachel Tate
Tweet
Dr. Dua reviews IgG4 disease involvement at #RWCS23 @RWCSmtg @RheumNow https://t.co/WHNSxhKGUU
Dr. John Cush
Tweet
Steroids assisting options - CTX, LEF or RTX @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/ENfg650B9A
Dr. John Cush
Tweet
IgG4 rel dz, steroid response is dramatic, but you need more than steroids for long term remission. @anisha_dua @RWCSmtg @RheumNow https://t.co/wq129L6DXT
Dr. John Cush
Tweet
IgG4 levels are often elevated and helpful, but not always. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/CcdPcxYIbl
Dr. John Cush
Tweet
IgG4 rel dz pathology. @anisha_dua @RWCSmtg @RheumNow https://t.co/LKIZ1BOejK
Dr. John Cush
Tweet
IgG4 related disease (a proliferative, fibrotic dz) manifestations by Dr Aisha Dua at RWCS @anisha_dua #rwcs23 @RWCSmtg @RheumNow https://t.co/hy6ZuOY2Ti
Dr. John Cush
Tweet
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
https://t.co/Ub9pUHPRrV https://t.co/5q2yrNLD5e
Dr. Rachel Tate
Tweet
While his talk didn’t focus on treatment, thoughtfulness regarding treatment for pain is important to our patients. Dr. Mease @RWCSmtg @RheumNow #RWCS23 https://t.co/f946SSeRWo
Dr. Rachel Tate
Tweet
Dr. Shenoi discusses a new bio markers in sJIA lung disease. #RWCS23 @RheumNow @RWCSmtg https://t.co/Nn3KjmGNfu
Dr. Rachel Tate
Tweet
How do you treat sJIA lung disease? Lots of steroids. Lung disease may stabilize but may not resolve. Dr. Shenoi @RWCSmtg #RWCS23 @RheumNow https://t.co/d5HiRy4Ud4
Dr. Rachel Tate
Tweet
MIS-c 2023 updated diagnostic criteria broken down by information type. Dr. Shenoi #RWCS23 @RheumNow @RWCSmtg https://t.co/U24sQiEF37
Dr. Rachel Tate
Tweet
Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 @RheumNow @RWCSmtg https://t.co/qMGA6IdtUE
Dr. Rachel Tate
Tweet
Sex differences in neutrophils could be an interesting approach to consider with our diseases. I personally had no idea my neutrophils may be different than a males. A very interesting thought by Dr. Postolova @RWCSmtg #RWCS23 @RheumNow https://t.co/mZsFaCBk7f
Dr. Rachel Tate
Tweet
“Remote patient monitoring should be here to stay.” Here are some important codes needed for your clinical practice. #RWCS23 @RheumNow @RWCSmtg @alvinwellsmd https://t.co/dj1CpU7ChY
Dr. John Cush
Tweet
Drug Safety Differences w/ New Therapies in RA
Safety outcomes for targeted synthetic or b/ts DMARDs used to treat RA were studied using data from the ARTIS registry.
https://t.co/U96LiasMhW https://t.co/f2oCHs04Q3
Dr. John Cush
Tweet
Comparison of MIS-C dz in kids and adults>21 (MISC - A). By Dr Susan Shenoi @RWCSmtg #rwcs23 https://t.co/jvsMLARkCA
Dr. John Cush
Tweet
Case reports of anifrolumab use in 2 pts w/ chronic, scarring discoid lupus unresponsive to steriods, HCQ, immunosuppressants & CTX. Case 1 SLEDAI from 13 to 2 in 24 weeks & CLASI-A from 26 to 3 in 20wks. Cs 2 CLASI-A decr 24 to 5 after 1 infusion https://t.co/JE3PVyskm4
